A survey of disease severity, quality of life, and treatment patterns of biologically naive patients with psoriasis in central and eastern Europe

Acta Dermatovenerologica Croatica

Volumn 18, Issue 3, 2010, Pages 151-162

  Palotai, Tamás ^a   Szepietowski, Jacek C ^b   Pec, Jurai ^c   Arenberger, Petr ^d   Giurcaneanu, Calin ^e   Gyulai, Rolland ^f   Miljkovic, Jovan ^g   Pärna, Ene ^h   Mikazans, Ingmars ⁱ   Grusauskas, Nauris ^j   Hodik, Michal ^a  

^a Wyeth Whitehall Medical Affairs   (Austria)

^b UNIVERSITY OF WROC AW   (Poland)

^c FACULTY HOSPITAL   (Slovakia)

^d CHARLES UNIVERSITY   (Czech Republic)

^e CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^f UNIVERSITY OF SZEGED   (Hungary)

^g UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^h TARTU UNIVERSITY HOSPITAL   (Estonia)

ⁱ PAULS STRADINS CLINICAL UNIVERSITY HOSPITAL   (Latvia)

^j Kaunas 2nd Clinical Hospital   (Lithuania)

more..

Author keywords

Anti TNF therapy; Biologicals; Disease severity; Patient profile; Psoriasis; Quality of life; TNF alpha inhibitors

Indexed keywords

BIOLOGICAL PRODUCT; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EMOLLIENT AGENT; KERATOLYTIC AGENT; METHOTREXATE;

ADULT; ARTICLE; BODY SURFACE; COMORBIDITY; CONTROLLED STUDY; CZECH REPUBLIC; DERMATOLOGY; DISEASE SEVERITY; DRUG MEGADOSE; EASTERN EUROPE; ESTONIA; FEMALE; HEALTH SURVEY; HUMAN; HUNGARY; LATVIA; LITHUANIA; MAJOR CLINICAL STUDY; MALE; PATIENT SATISFACTION; PHOTOTHERAPY; POLAND; PSORIASIS; QUALITY OF LIFE; QUESTIONNAIRE; ROMANIA; SLOVAKIA; SLOVENIA; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADULT; DATA COLLECTION; DRUG SUBSTITUTION; EUROPE, EASTERN; FEMALE; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; PSORIASIS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78149313141     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Menter A, Smith C, Barker J. Psoriasis. Oxford: Health Press Limited; 2004.
2. www.psoriasis.org.
3. Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73.
4. Yip SY. The prevalence of psoriasis in the Mongoloid race. J Am Acad Dermatol 1984;10:965-8.
5. Gelfand JM, Stern RS, Nijsten T, Feldman SR, Thomas J, Kist J, et al. The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol 2005;52:23-6.
6. Smith CH, Anstey AV, Barker JN, Burden AD, Chalmers RJ, Chandler D, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-97.
7. Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychologi-cal distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004;122:602-7.
8. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a sub-stantial burden even when not extensive, and is associated with widespread treatment dissa-tisfaction. J Invest Dermatol 2004;9:136-9
9. Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic me-asures are necessary to assess overall psoria-sis severity. J Am Acad Dermatol 2001;45:72-6.
10. Choi J, Koo JY. Quality of life issues in psoria-sis. J Am Acad Dermatol 2003;49:S57-61
11. Rapp SR, Feldman SR, Exum ML, Fleischer AB, Jr., Reboussin DM. Psoriasis causes as much disability as other major medical di-seases. J Am Acad Dermatol 1999;41:401-7
12. Griffiths CE, Clark CM, Chalmers RJ, Li Wan Po A, Williams HC. A systematic review of treatments for severe psoriasis. Health Techno-logy Assessment 2000;4:1-125.
13. Nederlandse Vereniging voor Dermatologie en Venerologie (NVDV) and the Institute for Healthcare Improvement (CBO). Dutch gui-deline for the treatment of severe psoriasis (ultraviolet B, ultraviolet A in combination with oral psoralen, cyclosporin A, methotrexate and acitretine): Van Zuiden Communications, ISBN 90-76906-88-2.
14. Nast A, Kopp I, Augustin M, Banditt KB, Bo-ehncke WH, Follmann M, et al. German evi-dence-based guidelines for the treatment of psoriasis vulgaris (short version). Arch Der-matol Res 2007;299:111-38.
15. Nast A, Kopp IB, Augustin M, Banditt KB, Bo-ehncke WH, Follmann M, et al. Evidence-ba-sed (S3) guidelines for the treatment of pso-riasis vulgaris. J Dtsch Dermatol Ges 2007;5 Suppl 3:1-119.
16. European Dermatology Forum (EDF). European S3 guidelines on the systemic treatment of psoriasis vulgaris. 2009.
17. Nast A, Spuls P, Ormerod A, Reytan N, Saiag P, Smith C, et al. A critical appraisal of evidence-based guidelines for the treatment of psoriasis vulgaris: 'AGREE-ing' on a common base for European evidence-based psoriasis treatment guidelines. J Eur Acad Dermatol Venereol 2009;23:1039-43.
18. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
19. Perrott SB, Murray AH, Lowe J, Mathieson CM. The psychosocial impact of psoriasis: physical severity, quality of life, and stigmati-zation. Physiol Behav 2000;70:567-71
20. Zachariae R, Zachariae H, Blomqvist K, Da-vidsson S, Molin L, Mork C, et al. Quality of life in 6497 Nordic patients with psoriasis. Br J Dermatol 2002;146:1006-16.
21. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997;137:755-60.
22. Augustin M, Kruger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multi-center cross-sectional study in Germany. Der-matology 2008;216:366-72.
23. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006;155:729-36
24. EUROPSO. http://www.europso.eu
25. NORDPSO-Nordic Alliance of Psoriasis Associations. Psoriasisförbundet, http://www. psoriasisforbundet.se/om-psoriasisforbundet/ internationellt-arbete/nordpso/.
26. National Psoriasis Foundation (NPF). http:// www.psoriasis.org/NetCommunity/Page. aspx?pid=798.
27. EUROPSO.http://www.europso.eu/index.php?section=home. Last accessed on 15-Dec-2009.
28. Pan European Psoriasis Patient Organization Forum (PE.Pso.POF). http://www.info-psoriasis.eu/index.php?option=com_content&task= view&id=13&Itemid=1. Last accessed on 15-Dec-2009.
29. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005;152:861-7
30. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-6.
31. Ashcroft DM, Wan Po AL, Williams HC, Grif-fiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:18591.
32. van de Kerkhof PCM. Clinical Features. In: Textbook of Psoriasis: Blackwell Publishing Ltd; 2003:3-29.
33. Espinoza LR, Cuellar ML, Silveira LH. Psoria-tic arthritis. Curr Opin Rheumatol 1992;4:470-8.
34. Golfieri R, Giampalma E, Tosti A, Calculli L, Berardi R, Gavelli G. Psoriasis arthropathica. A review of the literature, general considera-tions and the authors' personal experience. Radiol Med 1992;84:228-35.
35. Radtke MA, Reich K, Blome C, Rustenbach S, Augustin M. Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey. J Eur Acad Dermatol Venereol 2009;23:683-91.
36. Gisondi P, Girolomoni G, Sampogna F, Tabolli S, Abeni D. Prevalence of psoriatic arthritis and joint complaints in a large population of Italian patients hospitalised for psoriasis. Eur J Dermatol 2005;15:279-83.
37. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rhe-um Dis 2005;64 Suppl 2:ii14-7.
38. Christophers E. Comorbidities in psoriasis. Clin Dermatol 2007;25:529-34.
39. Alexandroff AB, Pauriah M, Camp RD, Lang CC, Struthers AD, Armstrong DJ. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol 2009;161:1-7.
40. Griffiths CE, Barker JN. Pathogenesis and clini-cal features of psoriasis. Lancet 2007;370:263-71.
41. Richards HL, Fortune DG, Griffiths CE, Main CJ. The contribution of perceptions of stigma-tisation to disability in patients with psoriasis. J Psychosom Res 2001;50:11-5.
42. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two conside-rations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoria-sis? J Am Acad Dermatol 2000;43:281-5.
43. Radtke MA, Reich K, Blome C, Kopp I, Rus-tenbach SJ, Schafer I, et al. Evaluation of qua-lity of care and guideline-compliant treatment in psoriasis. Development of a new system of quality indicators. Dermatology 2009;219:54-8.
44. Nast A, Reytan N, Rosumeck S, Erdmann R, Rzany B. Low prescription rate for systemic treatments in the management of severe pso-riasis vulgaris and psoriatic arthritis in derma-tological practices in Berlin and Brandenburg, Germany: results from a patient registry. J Eur Acad Dermatol Venereol 2008;22:1337-42
45. Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schafer I, et al. Quality of pso-riasis care in Germany -results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 2008;6:640-5.
46. Zachariae H, Zachariae R, Blomqvist K, Da-vidsson S, Molin L, Mork C, et al. Treatment of psoriasis in the Nordic countries: a ques-tionnaire survey from 5739 members of the psoriasis associations data from the Nordic Quality of Life Study. Acta Derm Venereol 2001;81:116-21.
47. Nast A, Erdmann R, Pathirana D, Rzany B. Translating psoriasis treatment guidelines into clinical practice-the need for educational interventions and strategies for broad dissemination. J Eval Clin Pract 2008;14:803-6
48. Kazandjieva J, Grozdev I, Darlenski R, Tsan-kov N. Climatotherapy of psoriasis. Clin Dermatol 2008;26:477-85.
49. Anstey A, George S. 'Real decisions' on pso-riasis care from informed clinicians. Br J Der-matol 2009;160:1139.
50. Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH. Economic evaluation of systemic th-erapies for moderate to severe psoriasis. Br J Dermatol 2009;160:1264-72.